OHSU's CNS disorder drug developer has launched with $76m from investors co-led by Arch Venture Partners and Cowen Healthcare Investments.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

The fraud prevention software provider closed a series A round co-led by Axa Venture Partners that will support international growth and product development.

Johnson & Johnson Innovation – JJDC returned for Cue Health’s $100m series C round as the medical diagnostics system developer seeks regulatory approval for its Covid-19 test.

The CNS disorder drug developer has launched with $76m from investors including Biogen, Bristol Myers Squibb and Pfizer Ventures.

GV co-led a series C round for the healthcare collaboration service together with F-Prime Capital, Andreessen Horowitz and Transformation Capital, taking its overall funding past $101m.

Stanford’s lysosome protein degradation spinout Lycia emerged with $50m of capital from Versant Ventures to develop a portfolio of drug candidates.

Existing backer GV returned to take part in a $100m round for the Stanford spinout that also attracted new investor Regeneron Pharmaceuticals.

The bank digitisation software provider Nymbus has now raised more than $45m in total, Vensure Enterprise co-leading its latest round.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.